Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing and lunch

117P - Age and ovarian function influence on fertility preservation attitude and outcome in breast cancer patients.

Date

12 May 2023

Session

Poster viewing and lunch

Presenters

gabriella gentile

Citation

Annals of Oncology (2023) 8 (1suppl_4): 101219-101219. 10.1016/esmoop/esmoop101219

Authors

G. gentile1, C. Tesei2, S. Brunetti2, P. Cavaceppi3, P. Marchetti4

Author affiliations

  • 1 Sapienza - Università di Roma, 00161 - Rome/IT
  • 2 Associazione Gemme Dormienti ONLUS, Rome/IT
  • 3 LabAurelia, Rome/IT
  • 4 Istituto Dermopatico dell'Immacolata IRCCS, 161 - Rome/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 117P

Background

A significant increase in breast cancer (BC) rates has been observed among pre-menopausal woman. Considering the higher number of patients (pts) who have not completed their family planning and impact of age on fertility, fertility preservation (FP) is proving to be a major challenge. Gemme Dormienti Onlus (GD) is an italian association that helps pts by promoting a valid model of FP counselling. Our aim was to identify age influence on ovarian function (OF) and FP in BC pts.

Methods

We analyzed 100 BC pts referred to GD. Pts were stratified by age in 3 groups: group 1 (G1) 18-29 years (y) (N= 15), group 2 (G2) 30-35 y (N=39), group 3 (G3) 36-39 y (N=46). All pts underwent basal laboratory and instrumental tests. FP options were gonadotropin-releasing hormone agonists (GnRHa) and/or cryopreservation of oocyte and/or cryopreservation of ovarian tissue (OTC).

Results

Basal follicle-stimulating hormone (FSH), anti-Müllerian hormone (AMH) and 17 beta-estradiol (E2) variations were affected by woman age in all groups [FSH (mU/ml): G1=3.6 (2.8-9.1), G2= 5.6 (1.5-12.4); G3= 5.9 (1.8-12.2); p= 0.323], [AMH (ng/ml): G1=6.0 (2.4-9.4); G2= 2.9 (1.0-7.6); G3= 4.0 (1.0-8.1); p= 0.099], [E2 (pg/ml): G1=89.0 (58.0-133.0), G2= 72.5 (11.0-511.3), G3= 50.8 (10.0-314.3), p=0.248]. Age-associated changes in antral follicular count (AFC) and endometrial thickness (ET) were clearly evident [Left-right AFC: G1=7.0 ± 3.1, 7.0 ± 5.3; G2= 4.0 ± 3.1, 4.0 ± 2.5; G3= 3.5 ± 2.5, 3.0 ± 4.2; p=<0.001, p=0.022], [ET (mm): G1=11.0 ± 2.9; G2= 9.0 ± 3.1; G3= 6.5 ± 3.0; p= 0.022]. All pts underwent GnRHa treatment, 30 pts oocyte cryopreservation (G1=40%, G2= 36.8%, G3=21.7%; p= 0.219); 18 OTC (G1=46.7%, G2=13.2%, G3=13%; p=0.008), 5 both techniques (G1=26.6%, G3=2.1). Lack of time (G2=15.8%; G3=12.9%), contraindications (G1=66.7%; G2= 47.4%; G3= 51.6%) and patient choice (G1=33.3%; G2= 36.8%; G3= 35.5%) were the main reasons for not starting FP. We observed 6 post-therapies pregnancies: 2 spontaneous in the G3 and 4 induced, 1 in G2 from OTC and 3 in G3 from oocyte cryopreservation.

Conclusions

Our data showed that FP counseling is a crucial need for BC premenopausal pts to express and realize the desire of pregnancy and improve a better quality of life.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.